Literature DB >> 11472982

Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling.

S J Wort1, M Woods, T D Warner, T W Evans, J A Mitchell.   

Abstract

Endothelin (ET)-1 is a potent vasoconstrictor and comitogen/ proliferation factor for vascular smooth muscle (VSM). As such, it has been implicated in the vascular wall remodeling observed in pulmonary hypertension (PH). Although the endothelium is considered the main source of ET-1, it can be released by other cells including VSM and may mediate proliferation in an autocrine manner. We investigated this possibility using human pulmonary artery smooth-muscle (HPASM) cells. Serum stimulated the release of ET-1 from HPASM cells in a concentration-dependent fashion and caused proliferation as determined by [(3)H]thymidine uptake and increase in cell number. Addition of an ET-A receptor antagonist (BQ123) or an inhibitor of ET-1 synthesis (phosphoramidon) reduced the proliferation induced by serum, confirming an autocrine role for ET-1. In addition, treatment of HPASM cells with two drug types used in the management of PH-cicaprost, a stable prostacyclin-mimetic; or diltiazem, a calcium-channel blocker-reduced ET-1 release from these cells. We conclude that ET-1 released from HPASM cells has an autocrine function in serum-induced proliferation, with important implications for the pathogenesis of human vascular remodeling. Drugs used in the treatment of PH may act, at least in part, by inhibiting this autocrine loop.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472982     DOI: 10.1165/ajrcmb.25.1.4331

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  21 in total

1.  Pulmonary artery smooth muscle cell endothelin-1 expression modulates the pulmonary vascular response to chronic hypoxia.

Authors:  Francis Y Kim; Elizabeth A Barnes; Lihua Ying; Chihhsin Chen; Lori Lee; Cristina M Alvira; David N Cornfield
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

2.  The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.

Authors:  Louise S Harrington; Laura Moreno; Anna Reed; Stephen J Wort; Béatrice Desvergne; Christopher Garland; Lan Zhao; Jane A Mitchell
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.752

3.  Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis.

Authors:  Emma Gibbons; S Promislow; Ross A Davies; George Chandy; Duncan J Stewart; Contreras-Dominguez Vladamir; Carolyn Pugliese; Rosemary Dunne; Lisa M Mielniczuk
Journal:  Can Respir J       Date:  2015-06-17       Impact factor: 2.409

4.  Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.

Authors:  S C Apostolopoulou; A Manginas; D V Cokkinos; S Rammos
Journal:  Heart       Date:  2005-03-10       Impact factor: 5.994

5.  Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.

Authors:  S C Apostolopoulou; A Manginas; D V Cokkinos; S Rammos
Journal:  Heart       Date:  2006-09-15       Impact factor: 5.994

6.  Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kappaB binding and histone acetylation at specific kappaB sites.

Authors:  Stephen J Wort; Misako Ito; Pai-Chien Chou; Shaun K Mc Master; Rekha Badiger; Elen Jazrawi; Patricia de Souza; Timothy W Evans; Jane A Mitchell; Liao Pinhu; Kaz Ito; Ian M Adcock
Journal:  J Biol Chem       Date:  2009-07-10       Impact factor: 5.157

Review 7.  Endothelin receptor antagonists for pulmonary arterial hypertension.

Authors:  Chao Liu; Junmin Chen; Yanqiu Gao; Bao Deng; Kunshen Liu
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 8.  Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review.

Authors:  N Fine; B Dias; G Shoemaker; S Mehta
Journal:  Can J Cardiol       Date:  2009-03       Impact factor: 5.223

9.  Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia.

Authors:  Koen Brusselmans; Veerle Compernolle; Marc Tjwa; Michael S Wiesener; Patrick H Maxwell; Désiré Collen; Peter Carmeliet
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

10.  Proteinase activated receptor-2 counterbalances the vascular effects of endothelin-1 in fibrotic tight-skin mice.

Authors:  Fiorentina Roviezzo; Vincenzo Brancaleone; Valentina Mattera Iacono; Antonio Bertolino; Giovanna De Cunto; Valentina Vellecco; Giuseppe Lungarella; Monica Lucattelli; Giuseppe Cirino
Journal:  Br J Pharmacol       Date:  2016-10-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.